glp-1 ra drugs list Drug Comparison in Diabetes and Obesity Treatment GLP-1 Agonists Explained: Definition, How

Diabetes, Obesity and Metabolism , 25 (1), 18-35

Given the observed increased risk of colorectal cancer among patients receiving GLP-1 receptor agonists, clinicians should approach long-term prescribing of these agents with careful consideration, particularly in individuals with additional risk factors for colorectal cancer, such as a family history, obesity, inflammatory bowel disease, or long-standing type 2 diabetes

The relationship between GLP-1 receptor agonists and mental health is complex

Despite concerns over affordability and side effects, in May, analysts at Morgan Stanley Research predicted the global obesity drug market could peak at $150 in 2035, up from the firms previous forecast of $105 billion

10.1016/j.molmet.2023.101805 Mol Metab

[DOI] [PubMed] [Google Scholar] 129.Levin PA, Mersey JH, Zhou S, Bromberger LA